자료유형  

 단행본

Control Number  

n887933136

International Standard Book Number  

030930301X electronic bk.

International Standard Book Number  

9780309303019 electronic bk.

International Standard Book Number  

9780309303002

International Standard Book Number  

0309303001

Library of Congress Call Number  

QH588.S83-S74 2013

Dewey Decimal Classification Number  

616.02/774-23

Main Entry-Meeting Name  

Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Unregulated Clinical Offerings (Workshop), (2013. Washington, D.C.)

Physical Description  

1 online resource (xx, 87 pages) : color illustrations

Bibliography, Etc. Note  

Includes bibliographical references.

Formatted Contents Note  

완전내용Introduction and themes of the workshop -- Stem cell therapies: knowns and unknowns -- Patients' experiences -- Comparative regulatory and legal frameworks -- The roles of professional societies -- Moving forward.

Summary, Etc.  

요약"Stem cells offer tremendous promise for advancing health and medicine. Whether being used to replace damaged cells and organs or else by supporting the body's intrinsic repair mechanisms, stem cells hold the potential to treat such debilitating conditions as Parkinson's disease, diabetes, and spinal cord injury. Clinical trials of stem cell treatments are under way in countries around the world, but the evidence base to support the medical use of stem cells remains limited. Despite this paucity of clinical evidence, consumer demand for treatments using stem cells has risen, driven in part by a lack of available treatment options for debilitating diseases as well as direct-to-consumer advertising and public portrayals of stem cell-based treatments. Clinics that offer stem cell therapies for a wide range of diseases and conditions have been established throughout the world, both in newly industrialized countries such as China, India, and Mexico and in developed countries such as the United States and various European nations. Though these therapies are often promoted as being established and effective, they generally have not received stringent regulatory oversight and have not been tested with rigorous trials designed to determine their safety and likely benefits. In the absence of substantiated claims, the potential for harm to patients - as well as to the field of stem cell research in general - may outweigh the potential benefits. To explore these issues, the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research held a workshop in November 2013. Stem Cell Therapies summarizes the workshop. Researchers, clinicians, patients, policy makers, and others from North America, Europe, and Asia met to examine the global pattern of treatments and products being offered, the range of patient experiences, and options to maximize the well-being of patients, either by protecting them from treatments that are dangerous or ineffective or by steering them toward treatments that are effective. This report discusses the current environment in which patients are receiving unregulated stem cell offerings, focusing on the treatments being offered and their risks and benefits. The report considers the evidence base for clinical application of stem cell technologies and ways to assure the quality of stem cell offerings."--Publisher's descriptions.

Subject Added Entry-Topical Term  

Stem cells Therapeutic use Congresses

Subject Added Entry-Topical Term  

Cellular therapy Congresses

Subject Added Entry-Topical Term  

Cellular therapy Law and legislation Congresses

Subject Added Entry-Topical Term  

Stem Cells Congresses

Subject Added Entry-Topical Term  

HEALTH & FITNESS Diseases General.

Subject Added Entry-Topical Term  

MEDICAL Clinical Medicine.

Subject Added Entry-Topical Term  

MEDICAL Diseases.

Subject Added Entry-Topical Term  

MEDICAL Evidence-Based Medicine.

Subject Added Entry-Topical Term  

MEDICAL Internal Medicine.

Added Entry-Personal Name  

Berger, Adam C.

Added Entry-Personal Name  

Beachy, Sarah H.

Added Entry-Personal Name  

Olson, Steve , 1956-

Added Entry-Corporate Name  

Institute of Medicine (U.S.) Board on Health Sciences Policy

Added Entry-Corporate Name  

National Research Council (U.S.) Board on Life Sciences

Added Entry-Corporate Name  

International Society for Stem Cell Research

Additional Physical Form Entry  

Print versionStem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Unregulated Clinical Offerings (Workshop) (2013 : Washington, D.C.). Stem cell therapies. Washington, D.C. : National Academies Press, [2014] 0309303001 (OCoLC)882531315

Electronic Location and Access  

로그인을 한후 보실 수 있는 자료입니다.

Control Number  

joongbu:441999